How semaglutide metabolism and CYP enzymes interact — and why it matters

Why semaglutide does not follow the usual CYP450 route

Most small-molecule medicines are processed in the liver by cytochrome P450 enzymes, a large family of proteins that oxidise foreign compounds so the body can excrete them. Semaglutide is not a small molecule. It is a modified GLP-1 receptor agonist peptide, roughly analogous in size and structure to a naturally occurring gut hormone, and the body treats it accordingly. If you want to understand how semaglutide metabolism works, including proteolytic cleavage and the role of fatty-acid side chains in albumin binding and prolonged half-life, that page covers the mechanism in full.

What this means in practice is that semaglutide does not inhibit, induce, or compete with CYP1A2, CYP2C8, CYP2C9, CYP3A4 or any of the other major isoenzymes that dominate drug-interaction tables. The published pharmacokinetic data, reviewed by regulators prior to UK licensing, found no clinically meaningful CYP-mediated interaction signal. The Wegovy SmPC on the electronic Medicines Compendium summarises this under the pharmacokinetic interactions section and is the authoritative source for prescribers and pharmacists.

This is genuinely good news for people already taking multiple medicines. Many patients who might benefit from semaglutide have type 2 diabetes, cardiovascular disease, or hypertension, conditions that typically come with complex medication regimens. The absence of direct CYP involvement removes an entire category of interaction risk that would otherwise require extensive modelling before co-prescribing.

Gastric emptying: the indirect interaction that does matter

Semaglutide slows gastric emptying. That is, in part, how it reduces appetite, food stays in the stomach longer, prolonging the feeling of fullness. The same mechanism, however, means that oral medicines swallowed alongside semaglutide take longer to reach the small intestine where absorption happens. For many medicines this delay is clinically irrelevant; for others, it is not.

The medicines where delayed absorption is worth flagging include those with narrow therapeutic windows, time-sensitive dosing requirements, or formulations designed to release quickly. Levothyroxine (taken by a large number of people managing hypothyroidism) is one example routinely raised in clinical discussion. Warfarin absorption may also be affected, though INR monitoring provides a practical safety net. If you are curious about whether semaglutide changes your metabolism, including how it influences energy expenditure beyond drug kinetics, that page covers the question in detail.

The practical implication is not that these combinations are forbidden. It is that timing, monitoring, and open disclosure matter. A prescriber who knows every medicine you take can assess the actual risk, adjust timing where needed, and flag whether any dose review is warranted. Concealing co-prescriptions during a consultation to avoid being refused treatment is the scenario that turns a theoretical interaction into a real one.

Oral contraceptives, the Wegovy tablet, and what UK guidance says

When semaglutide is taken as an injection (Wegovy), the evidence does not currently support a meaningful reduction in oral contraceptive efficacy specifically attributed to semaglutide, unlike tirzepatide (Mounjaro), for which UK guidance advises adding a non-oral contraceptive method for the first four weeks of each dose increase. Injectable semaglutide sits differently in this respect, and NHS England's guidance on weight-management injections addresses contraception and HRT considerations in detail.

The oral Wegovy tablet adds a further consideration. Because it is absorbed in the stomach itself (an unusual property enabled by its SNAC co-formulation) it must be taken first thing in the morning with a small sip of plain water, and nothing else (including coffee or other medicines) for at least 30 minutes afterwards. Patients who keep it in a bag beside the bedside table, and take it before their feet hit the floor, tend to find this easiest to sustain. Concurrent oral medicines should be timed accordingly, which is another reason full co-prescription disclosure matters from the outset.

For a broader picture of the evidence on whether Wegovy helps with metabolism, including lean mass and resting energy expenditure, that context is worth reading alongside the interaction data here.

What this means before you start semaglutide

The reassuring headline is that semaglutide's freedom from CYP-mediated interactions makes it, metabolically speaking, one of the cleaner options in a complex medication history. But the gastric-emptying effect is real, and the list of medicines where it deserves attention is longer than most people realise when they first ask about weight-loss treatment.

Disclosing your full medication list (including supplements, herbal products, and anything bought without a prescription) at the point of clinical review is not box-ticking. It is the step that lets your prescriber make a genuinely personalised call rather than a population-level one. You can explore semaglutide and Wegovy in detail on their dedicated pages, including eligibility, the licensed dosing schedule, and results evidence from the STEP programme. For an overview of all weight-loss treatment options available through nume, including how they compare, that is a useful starting point before a consultation.

If you do have a complex medicine history and want a clinical view on how Wegovy affects your metabolism alongside other considerations, our prescribers are best placed to give it. Speak to our prescribers through a free consultation, every application is personally reviewed, not processed by an algorithm.